Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001213900-25-012191·ESSA Pharma Inc.
Schedule 13G ownership disclosure
ESSA PHARMA INC
Common Stock, par value $0.0001 per share · CUSIP: 29668H708
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Soleus Capital Special Opportunities Fund, L.P.
Shares: 0.00 · Class: 0%
- Soleus Capital Master Fund, L.P.
Shares: 2,262,026.00 · Class: 5.1%
- Soleus Capital, LLC
Shares: 2,262,026.00 · Class: 5.1%
- Soleus Capital Group, LLC
Shares: 2,262,026.00 · Class: 5.1%
- Soleus Capital Management, L.P.
Shares: 2,262,026.00 · Class: 5.1%
- Soleus GP LLC
Shares: 2,262,026.00 · Class: 5.1%
- Guy Levy
Shares: 2,262,026.00 · Class: 5.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-012191
- Form type
- SCHEDULE 13G/A
- Filer
- ESSA Pharma Inc.
- CIK
- CIK 1633932
- Filed
- Feb 11, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership